{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:24:12Z","timestamp":1788387852453,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T00:00:00Z","timestamp":1520553600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1038\/s41409-018-0122-8","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T10:36:13Z","timestamp":1520246173000},"page":"749-755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC"],"prefix":"10.1038","volume":"53","author":[{"given":"Karine","family":"Augeul-Meunier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Lorraine","family":"Chretien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Stoppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lofti","family":"Benboubker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Miguel Torregrosa","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude-Eric","family":"Bulabois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis Peffault","family":"de Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Cornillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,9]]},"reference":[{"issue":"13","key":"122_CR1","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"34","author":"Meletios A. Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016; \n                    https:\/\/doi.org\/10.1200\/JCO.2015.65.0044","journal-title":"Journal of Clinical Oncology"},{"key":"122_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/annonc\/mdt483","volume":"25","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol. 2014;25:195\u2013200.","journal-title":"Ann Oncol"},{"key":"122_CR3","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/ajh.24035","volume":"90","author":"BA Zannetti","year":"2015","unstructured":"Zannetti BA, Zamagni E, Santostefano M, De Sanctis LB, Tacchetti P, Mancini E, et al. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. Am J Hematol. 2015;90:647\u201352.","journal-title":"Am J Hematol"},{"key":"122_CR4","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311\u201320.","journal-title":"N Engl J Med"},{"key":"122_CR5","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","volume":"114","author":"A Badros","year":"2001","unstructured":"Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114:822\u20139.","journal-title":"Br J Haematol"},{"key":"122_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/sj.bmt.1700950","volume":"20","author":"OF Ballester","year":"1997","unstructured":"Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC, et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant. 1997;20:653\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"122_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1365-2141.2006.06191.x","volume":"134","author":"JM Bird","year":"2006","unstructured":"Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a british society of blood and marrow transplantation study. Br J Haematol. 2006;134:385\u201390.","journal-title":"Br J Haematol"},{"key":"122_CR8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.clml.2015.03.003","volume":"15","author":"R El Fakih","year":"2015","unstructured":"El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, et al. Autologous hematopoietic stem cell transplantation in dialysis-dependent myeloma patients. Clin Lymphoma Myeloma Leuk. 2015;15:472\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"122_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/sj.bmt.1705627","volume":"39","author":"MA Gertz","year":"2007","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Leung N, et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2007;39:605\u201311.","journal-title":"Bone Marrow Transplant"},{"key":"122_CR10","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/bmt.2013.109","volume":"48","author":"SV Glavey","year":"2013","unstructured":"Glavey SV, Gertz MA, Dispenzieri A, Kumar S, Buadi F, Lacy M, et al. Long-term outcome of patients with multiple [corrected] myeloma-related advanced renal failure following auto-SCT. Bone Marrow Transplant. 2013;48:1543\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"122_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0609.2005.00446.x","volume":"75","author":"LM Knudsen","year":"2005","unstructured":"Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol. 2005;75:27\u201333.","journal-title":"Eur J Haematol"},{"key":"122_CR12","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/sj.bmt.1704440","volume":"33","author":"CK Lee","year":"2004","unstructured":"Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. 2004;33:823\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"122_CR13","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.bbmt.2009.03.021","volume":"15","author":"GC Parikh","year":"2009","unstructured":"Parikh GC, Amjad AI, Saliba RM, Kazmi SMA, Khan ZU, Lahoti A, et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15:812\u20136.","journal-title":"Biol Blood Marrow Transplant"},{"key":"122_CR14","first-page":"1555","volume":"91","author":"MS Raab","year":"2006","unstructured":"Raab MS, Breitkreutz I, Hundemer M, Benner A, Klaus J, Hegenbart U, et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica. 2006;91:1555\u20138.","journal-title":"Haematologica"},{"key":"122_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/sj.thj.6200003","volume":"1","author":"JF San Miguel","year":"2000","unstructured":"San Miguel JF, Lahuerta JJ, Garc\u00eda-Sanz R, Alegre A, Blad\u00e9 J, Martinez R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J. 2000;1:28\u201336.","journal-title":"Hematol J"},{"key":"122_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/bmt.2014.226","volume":"50","author":"R Bernard St","year":"2015","unstructured":"St Bernard R, Chodirker L, Masih-Khan E, Jiang H, Franke N, Kukreti V, et al. Efficacy, toxicity and mortality of autologous sct in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant. 2015;50:95\u201399.","journal-title":"Bone Marrow Transplant"},{"key":"122_CR17","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/bmt.2016.136","volume":"51","author":"K Sweiss","year":"2016","unstructured":"Sweiss K, Patel S, Culos K, Oh A, Rondelli D, Patel P. Melphalan 200\u2009Mg\/m2 in patients with renal impairment is associated with increased short-term toxicity but improved response and longer treatment-free survival. Bone Marrow Transplant. 2016;51:1337\u201341.","journal-title":"Bone Marrow Transplant"},{"key":"122_CR18","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"122_CR19","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1182\/blood-2010-08-300863","volume":"117","author":"P Moreau","year":"2011","unstructured":"Moreau P, Attal M, P\u00e9gouri\u00e9 B, Planche L, Hulin C, Facon T, et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood. 2011;117:3041\u20134.","journal-title":"Blood"},{"key":"122_CR20","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","volume":"28","author":"JL Harousseau","year":"2010","unstructured":"Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28:4621\u20139.","journal-title":"J Clin Oncol"},{"key":"122_CR21","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/bmt.2014.165","volume":"49","author":"I Breitkreutz","year":"2014","unstructured":"Breitkreutz I, Heiss C, Perne A, Beimler J, J\u00e4ger D, Egerer G, et al. Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure. Bone Marrow Transplant. 2014;49:1371\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"122_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3324\/haematol.2013.087585","volume":"99","author":"C Scheid","year":"2014","unstructured":"Scheid C, Sonneveld P, Schmidt-Wolf IGH, van der Holt B, el Jarari L, Bertsch U, et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65\/GMMG-HD4 trial. Haematologica. 2014;99:148\u201354.","journal-title":"Haematologica"},{"key":"122_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/leu.2012.182","volume":"27","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27:423\u20139.","journal-title":"Leukemia"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0122-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0122-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0122-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:11:34Z","timestamp":1684617094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0122-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,9]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["122"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0122-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,9]]},"assertion":[{"value":"16 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}